BPMC Quote, Financials, Valuation and Earnings

Agios Pharmaceuticals has a net margin of -34.13% compared to Blueprint Medicines's net margin of -899.56%. Blueprint Medicines's return on equity of -24.43% beat Agios Pharmaceuticals's return on equity of 62.58%.

Blueprint Medicines has a consensus price target of $124.90, signalling upside risk potential of 42.48%. On the other hand Agios Pharmaceuticals has an analysts' consensus of $53.32 which suggests that it could grow by 81.04%. Given that Agios Pharmaceuticals has higher upside potential than Blueprint Medicines, analysts believe Agios Pharmaceuticals is more attractive than Blueprint Medicines.

Blueprint Medicines has a beta of 0.746, which suggesting that the stock is 25.37% less volatile than S&P 500. In comparison Agios Pharmaceuticals has a beta of 0.831, suggesting its less volatile than the S&P 500 by 16.932%.

Blueprint Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agios Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Blueprint Medicines pays -- of its earnings as a dividend. Agios Pharmaceuticals pays out -- of its earnings as a dividend.

Blueprint Medicines quarterly revenues are $146.4M, which are larger than Agios Pharmaceuticals quarterly revenues of $10.7M. Blueprint Medicines's net income of -$50M is higher than Agios Pharmaceuticals's net income of -$96.5M. Notably, Blueprint Medicines's price-to-earnings ratio is -- while Agios Pharmaceuticals's PE ratio is 2.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Blueprint Medicines is 10.92x versus 46.48x for Agios Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Alnylam Pharmaceuticals has a net margin of -34.13% compared to Blueprint Medicines's net margin of -14.12%. Blueprint Medicines's return on equity of -24.43% beat Alnylam Pharmaceuticals's return on equity of --.

Blueprint Medicines has a consensus price target of $124.90, signalling upside risk potential of 42.48%. On the other hand Alnylam Pharmaceuticals has an analysts' consensus of $316.87 which suggests that it could grow by 25.96%. Given that Blueprint Medicines has higher upside potential than Alnylam Pharmaceuticals, analysts believe Blueprint Medicines is more attractive than Alnylam Pharmaceuticals.

Blueprint Medicines has a beta of 0.746, which suggesting that the stock is 25.37% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals has a beta of 0.300, suggesting its less volatile than the S&P 500 by 70.047%.

Blueprint Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Blueprint Medicines pays -- of its earnings as a dividend. Alnylam Pharmaceuticals pays out -- of its earnings as a dividend.

Blueprint Medicines quarterly revenues are $146.4M, which are smaller than Alnylam Pharmaceuticals quarterly revenues of $593.2M. Blueprint Medicines's net income of -$50M is higher than Alnylam Pharmaceuticals's net income of -$83.8M. Notably, Blueprint Medicines's price-to-earnings ratio is -- while Alnylam Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Blueprint Medicines is 10.92x versus 14.28x for Alnylam Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -34.13% compared to Blueprint Medicines's net margin of --. Blueprint Medicines's return on equity of -24.43% beat Palatin Technologies's return on equity of --.

Blueprint Medicines has a consensus price target of $124.90, signalling upside risk potential of 42.48%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 3281.64%. Given that Palatin Technologies has higher upside potential than Blueprint Medicines, analysts believe Palatin Technologies is more attractive than Blueprint Medicines.

Blueprint Medicines has a beta of 0.746, which suggesting that the stock is 25.37% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

Blueprint Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Blueprint Medicines pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Blueprint Medicines quarterly revenues are $146.4M, which are larger than Palatin Technologies quarterly revenues of --. Blueprint Medicines's net income of -$50M is higher than Palatin Technologies's net income of --. Notably, Blueprint Medicines's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Blueprint Medicines is 10.92x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Sutro Biopharma has a net margin of -34.13% compared to Blueprint Medicines's net margin of -489.18%. Blueprint Medicines's return on equity of -24.43% beat Sutro Biopharma's return on equity of -204.67%.

Blueprint Medicines has a consensus price target of $124.90, signalling upside risk potential of 42.48%. On the other hand Sutro Biopharma has an analysts' consensus of $3.43 which suggests that it could grow by 279.86%. Given that Sutro Biopharma has higher upside potential than Blueprint Medicines, analysts believe Sutro Biopharma is more attractive than Blueprint Medicines.

Blueprint Medicines has a beta of 0.746, which suggesting that the stock is 25.37% less volatile than S&P 500. In comparison Sutro Biopharma has a beta of 1.697, suggesting its more volatile than the S&P 500 by 69.657%.

Blueprint Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sutro Biopharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Blueprint Medicines pays -- of its earnings as a dividend. Sutro Biopharma pays out -- of its earnings as a dividend.

Blueprint Medicines quarterly revenues are $146.4M, which are larger than Sutro Biopharma quarterly revenues of $14.8M. Blueprint Medicines's net income of -$50M is higher than Sutro Biopharma's net income of -$72.4M. Notably, Blueprint Medicines's price-to-earnings ratio is -- while Sutro Biopharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Blueprint Medicines is 10.92x versus 1.12x for Sutro Biopharma. Usually stocks with elevated PS ratios are considered overvalued.